Company intelligence / Profile preview
Exsulin
Burnsville, Minnesota, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Exsulin developed a peptide-based therapy (INGAP peptide) aimed at regenerating insulin-producing islets in patients with type 1 and type 2 diabetes. Phase II clinical trials showed statistically significant improvements in C-peptide levels and A1C reduction, suggesting restoration or preservation of endogenous insulin secretion. The company targeted both new-onset and established type 1 diabetes patients, with studies conducted at Mayo Clinic and McGill University. There have been no recent clinical updates since the early-to-mid 2010s.
- Therapeutic areas
- Endocrinology
- Modalities
- PeptidesProtein (peptide-based drug)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Mayo Clinic (clinical trial site)McGill University (clinical trial site)
Beyond the preview
Go deeper on Exsulin.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Exsulin.